Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (256)	4/20/2007 6:31:46 AM
From: kenhott	Read Replies (1) \| Respond to of 295

Here's the PR: Neurochem Update on the North American Phase III Clinical Trial for Tramiprosate (ALZHEMED(TM)) for the Treatment of Alzheimer's Disease Thursday April 19, 7:00 am ET LAVAL, QC, April 19 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX - News; TSX: NRM - News) announces that the database for the North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease has been locked. The analysis is ongoing and entails employing an accurate statistical model that appropriately describes the data and provides accurate results. Neurochem has been advised by its external team of statisticians that adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors such as the effect of concomitant medications, baseline characteristics of the study population or differences in clinical sites. Neurochem points out that potential refinement of the statistical model was discussed with the U.S. Food and Drug Administration before filing with the Agency and was anticipated in the plan filed. The Company notes that in a clinical trial of the size, duration and complexity of the tramiprosate (ALZHEMED(TM)) Phase III study, such a process is not uncommon. The Company has been informed that it could take several weeks, perhaps longer, before the results are known. Neurochem continues to expect to announce these results during the second quarter of this year. -------------------------- First, you can't short this stock anymore. Second, if I could short more and I tried, I would. Third, they are lying. Yes everything is true as the PR is written but it is written with bull cookie ink. They have top line data in house and don't like it. Without much of a doubt, the trial failed top line ITT. So this PR is saying we will look for supportive data which will not be supported by the FDA no matter how they wrote this PR. If they could, they would wait for the EU trial to see if that will save their bacon. Maybe they will PR that outside astrologists have recommended they wait till Dec 07 for data release due to the star alignment charts. And BTW, that was also in the stat plan submitted to the FDA. Fourth, may be they will help their existing shareholders but financing before the astrological event.